ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer treatments designed to overcome tumor resistance. ORIC has no approved products and generates no product revenue; the company is entirely R&D-funded through equity capital raised in public markets. ORIC's two lead drug candidates are rinzimetostat and enozertinib. Rinzimetostat is an oral PRC2 inhibitor being developed in combination with approved androgen receptor inhibitors for metastatic castration-resistant prostate cancer, with a Phase 3 trial expected to begin in H1 2026. Enozertinib is a brain-penetrant, oral EGFR inhibitor targeting exon 20 insertions and atypical PACC mutations in non-small cell lung cancer, with a key differentiator being its ability to cross the blood-brain barrier to address CNS metastases — a limitation of currently approved options. Phase 3 monotherapy dosing has been selected, and combination data with Johnson & Johnson's amivantamab is expected in H2 2026. ORIC in-licensed rinzimetostat from Mirati with no milestones or royalties owed, and enozertinib from Voronoi with milestone and royalty obligations. Johnson & Johnson and Bayer supply their approved drugs for ORIC's combination trials at no cost, while ORIC retains full economic ownership of rinzimetostat. ORIC has deprioritized its preclinical discovery group to focus spending on these two programs, and also holds two out-licensed candidates it is seeking partners to develop.